Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 8/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965729 | 1.00 | MEN1 (0.56) | MEN1KMT2APOLBBTKRAB9A | |
| SCHEMBL123441 | 0.83 | BTK (0.54) | MEN1KMT2APOLBBTKJAK2 | |
| SCHEMBL23725318 | 0.81 | MEN1 (0.40) | MEN1KMT2APOLBBTKJAK2 | |
| SCHEMBL6753728 | 0.81 | POLB (0.62) | MEN1KMT2APOLBBTKRAB9A | |
| SCHEMBL23726015 | 0.80 | HPGD (0.46) | MEN1KMT2ABTKGAA | |
| SCHEMBL16336359 | 0.79 | BTK (0.52) | MEN1KMT2APOLBBTKJAK2 | |
| SCHEMBL29436997 | 0.76 | POLB (0.64) | MEN1KMT2APOLBBTKRAB9A | |
| SCHEMBL19409427 | 0.76 | POLB (0.64) | MEN1KMT2APOLBBTKRAB9A | |
| SCHEMBL9983255 | 0.75 | BTK (0.52) | MEN1KMT2APOLBBTKRAB9A | |
| SCHEMBL29709475 | 0.75 | BTK (0.52) | MEN1KMT2APOLBBTKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368362-A | Quinoxalinone derivatives as BTK inhibitors and application thereof | 华东理工大学 | 2022-11-22 | — | — | CN | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | disclosed |
| EP-2582668-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2391602-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | MEN1 3158/4885KMT2A 561/4885POLB 3512/4885 |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, PRKACA, CILK1 | MEN1 2270/4885KMT2A 421/4885POLB 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.